恆瑞醫藥(600276.SH):長效抗真菌藥注射用HRS9432獲批臨牀
格隆匯8月12日丨恆瑞醫藥(600276.SH)公佈,公司子公司福建盛迪醫藥有限公司近日收到國家藥監局核准簽發關於注射用HRS9432的《藥物臨牀試驗批准通知書》,將於近期開展臨牀試驗。
注射用HRS9432擬用於念珠菌血症和/或侵襲性念珠菌病的預防和治療。目前,已上市抗真菌藥物臨牀治療中,部分真菌已出現耐藥性,注射用HRS9432作為新一代長效抗真菌藥物,能夠為患者提供更多的治療方案,並且能夠延長給藥週期。經查詢,國內外未有同類長效產品獲批上市,亦無相關銷售數據。
截至目前,注射用HRS9432相關研發項目累計已投入研發費用約為1988萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.